- The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV–011, a clinical Phase 1 investigational novel compound with broad [...] Read more »
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
- Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu–PSMA–I&T and 64Cu–PSMA–I&T
- Builds on long–standing [...] Read more »
Um novo relatório da “Access to Medicine Foundation” revela como os esforços de acesso das empresas farmacêuticas estão centrados nos pacientes
AMESTERDÃO, Sept. 10, 2024 (GLOBE NEWSWIRE) — O mais recente relatório da Access to Medicine Foundation analisa, pela primeira vez, a questão crítica de como algumas das maiores empresas farmacêuticas [...] Read more »
Un nouveau rapport de l’Access to Medicine Foundation révèle à quel point les efforts des entreprises pharmaceutiques en matière d’accès aux médicaments sont axés sur les patients
AMSTERDAM, 10 sept. 2024 (GLOBE NEWSWIRE) — Le dernier rapport de l’Access to Medicine Foundation se penche pour la première fois sur la question cruciale de l’approche de certaines des plus grandes entreprises [...] Read more »
Neuer Bericht der Access to Medicine Foundation zeigt Einsatz von Pharmaunternehmen für einen besseren Zugang zu Medikamenten für Patienten
AMSTERDAM, Sept. 10, 2024 (GLOBE NEWSWIRE) — Der neueste Bericht der Access to Medicine Foundation wirft erstmals einen Blick auf die entscheidende Frage, wie einige der größten Pharmaunternehmen Patienten weltweit [...] Read more »
A new report from the Access to Medicine Foundation reveals how patient-focused pharma companies' access efforts are
AMSTERDAM, Sept. 10, 2024 (GLOBE NEWSWIRE) — The latest report from the Access to Medicine Foundation takes a first–ever look at the critical issue of how some of the largest pharmaceutical companies are reaching [...] Read more »